Biome Australia eyes best day ever on positive trial results for asthma treatment

Biome Australia

02/02/2022 03:58

** Shares of Biome Australia Ltd  BIO.AX  rise as much as
14.3% to A$0.120, set for their best session ever 
    ** Biotech service co says independent clinical trial
results demonstrate efficacy of a targeted probiotic in
treatment of asthma in children  urn:newsml:reuters.com:*:nASX4cqS3F
    ** Says use of Biome Breathe Probiotic led to 64.2%
reduction in asthma exacerbations
    ** Says clinical validation opens commercial opportunities
for co 
    ** Stock hits highest level since Jan. 20 
    ** As of last close, stock down 12.5% this year

 (Reporting by Navya Mittal)
 ((Navya.Mittal@thomsonreuters.com;))